The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis

Published:2021-06 Issue:6 Volume:79 Page:783-792
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Mori Keiichiro,Abufaraj Mohammad,Mostafaei Hadi,Quhal Fahad,Fajkovic Harun,Remzi Mesut,Karakiewicz Pierre I.,Egawa Shin,Schmidinger Manuela,Shariat Shahrokh F.,Gust Kilian M.

Publisher

Elsevier BV

Subject

Urology

Reference47 articles.

1. European Association of Urology guidelines on renal cell carcinoma: the 2019 update;Ljungberg;Eur Urol,2019

2. A non-cancer-related survival benefit is associated with partial nephrectomy;Sun;Eur Urol,2012

3. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study;Capitanio;BJU Int,2009

4. Resistance to checkpoint inhibition in cancer immunotherapy;Barrueto;Transl Oncol,2020

5. The immunobiology of kidney cancer;Drake;J Clin Oncol,2018

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study;Biomolecules and Biomedicine;2024-06-25

2. Highly expressed of BID indicates poor prognosis and mediates different tumor microenvironment characteristics in clear cell renal cell carcinoma;Discover Oncology;2024-05-20

3. Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma;Medical Oncology;2024-05-13

4. Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors;Expert Review of Anticancer Therapy;2024-04-17

5. PD-L1 as a Urine Biomarker in Renal Cell Carcinoma—A Case Series and Proof-of-Concept Study;Diagnostics;2024-03-30